Siegfried Pharma Development GmbH, a subsidiary of Siegfried Ltd, is located in Munich and focuses on the development, registration and manufacture of generics for pulmonary applications.
An innovative dry powder inhaler (DPI), registered and patented under the name PulmoJetŪ, serves as technology platform. PulmoJetŪ is being developed with the goal to obtain a simple to use and robust device with excellent performance and patient feedback features, while retaining simplicity in construction and cost-effectiveness in manufacture.
